Lipid-modulate activity of Cichorium glandulosum Boiss. et Huet polysaccharide in nonalcoholic fatty liver disease larval zebrafish model.

Abstract

Nonalcoholic fatty liver disease (NAFLD)1 is the most common chronic liver disease worldwide. Cichorium glandulosum Boiss. et Huet (CG) is a common traditional Uighur medicine, and it has been widely used as active therapy on various hepatic diseases. Recently, lipid-lowering effect has been revealed on CG. Polysaccharides are principal component of CG which could be the possible lipid-lowering compound in CG. In this study, extraction and purification of CG polysaccharides (CGP) was performed, and the lipid regulation effect of CGP was investigated on NAFLD zebrafish model. The results showed that CGP significantly decreased the levels of TC, TG, and decreased the mRNA expression of srebf-1, and fas, increased the expression of pparab. The findings suggest that the lipid-lowering effects of CGP mainly depend on facilitation of lipolysis (mainly beta-oxidation) or inhibition of lipogenesis. Furthermore, CGP could prevent and causes the regression of steatosis in NAFLD via its lipid metabolism regulation effect.

• Authors: Maoru Li, Ji Ma, Owais Ahmad, Yi Cao, Bing Wang, Qiangqiang He, Jiajing Li, Hongli Yin, Yifan Zhang, Jiang He, Jing Shang
• Journal: Journal of pharmacological sciences (J Pharmacol Sci) Vol. 138 Issue 4 Pg. 257-262 (Dec 2018) ISSN: 1347-8648 [Electronic] Japan
• PMID: 30482436 (Publication Type: Journal Article)
• Copyright: Copyright © 2018 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Chemical References

• Hypolipidemic Agents
• Polysaccharides

Topics

• Animals
• Asteraceae
• Disease Models, Animal
• Hypolipidemic Agents (pharmacology, therapeutic use)
• Larva
• Lipid Metabolism (drug effects)
• Non-alcoholic Fatty Liver Disease (drug therapy, genetics, metabolism)
• Phytotherapy
• Polysaccharides (pharmacology, therapeutic use)
• Transcriptome (drug effects)
• Zebrafish